论文部分内容阅读
目的探讨改善晚期胰腺癌预后的有效治疗措施。方法４３例晚期胰腺癌患者采用转流手术、动脉灌注化疗或联合术中癌内注射和围手术期免疫调节综合治疗，随访生存期与对照组病例比较。结果４３例患者术后生活质量明显提高，无治疗相关并发症。术后平均生存期１１．４±７．３月，１、２、３年生存率分别为３０．２％、９．３％、２．３％，生存期明显延长。结论动脉灌注化疗联合围手术期免疫调节综合治疗，有助于改善晚期胰腺癌患者的预后，是一种安全有效的新方法。
Objective To explore effective treatment measures for improving the prognosis of advanced pancreatic cancer. Methods Forty-three patients with advanced pancreatic cancer underwent bypass surgery, arterial infusion chemotherapy or combined intra-operative injection and perioperative immunomodulatory treatment. The follow-up survival period was compared with that of the control group. Results The postoperative quality of life was significantly improved in 43 patients without treatment-related complications. The average survival time was 11.4±7.3 months. The 1-, 2-, and 3-year survival rates were 30.2%, 9.3%, and 2.3%, respectively. The survival period was significantly longer. Conclusion Arterial infusion chemotherapy combined with perioperative immunomodulatory therapy can improve the prognosis of patients with advanced pancreatic cancer. It is a safe and effective new method.